Hook / Thesis
XP Inc. is an atypical Brazil-focused wealth platform that, today at $16.97, offers a buyable combination of growth optionality and cheap valuation. The company has been extending its addressable market beyond retail Brazil - moving into international clients, institutional flows and on-chain product distribution - while keeping profitability intact. At a market cap of roughly $8.8 billion and a P/E near 9.2x, the risk/reward for a mid-term swing trade looks favorable.
Our trade thesis: buy XP at the market ($16.97) with a mid-term target of $21 and a stop at $15. The setup is supported by improving asset growth trends, a resilient net income profile (record Q2 profit in 2025), an attractive valuation vs. historical and global peers, and technicals that show constructive momentum. That said, material legal and regulatory overhangs and macro sensitivity to Brazil rates and FX require disciplined stops and position sizing.
Business summary - what XP does and why it matters
XP is a technology-driven financial services platform headquartered in Vila Olímpia, Sao Paulo. The firm operates two principal offerings: advisory services for retail, high-net-worth, international and institutional clients, and an open product distribution platform that gives access to more than 800 investment products (equities, fixed income, funds, structured products, insurance and pension plans). This model creates recurring fee streams from advisory and distribution fees, while also enabling AUM (assets under management) and product sales to scale without a linear cost base.
The market should care because XP is not just a broker: it is a full-stack distribution and advisory platform that can monetize asset growth, cross-sell proprietary products and harvest higher-margin revenue as clients’ asset mixes shift. The company's strategic moves - including partnerships to tokenize assets and expand payment rails - accelerate optionality to capture fee income in new formats and geographies.
What the numbers show
Key snapshot metrics:
| Metric | Figure |
|---|---|
| Current price | $16.97 |
| Market cap | $8.77B |
| P/E ratio | 9.24x |
| P/B ratio | 1.86x |
| Shares outstanding | 517,015,469 |
| Dividend (per share) | $0.20 (record: 06/10/2026, payable: 06/18/2026) |
| 52-week range | $14.80 - $23.13 |
Recent performance and fundamentals are constructive: the company reported record Q2 net income in 2025 (BRL 1.321 billion) and expanded net margins in that period, and commentary and subsequent coverage indicate 22% year-over-year asset growth and 15% net income growth across 2025. Those data points point to a business that can grow AUM and profit at a healthy clip while still trading at single-digit P/E multiples (9.24x), which compares favorably to global wealth management peers and suggests multiple expansion is possible if growth continues.
Technical and market context
On the tape, XP shows a constructive technical setup: current price sits slightly above short-term moving averages (SMA10 $16.893, SMA20 $16.7405, SMA50 $16.3035) and the RSI is neutral at ~53.8. MACD shows bullish momentum (MACD line 0.158 vs signal 0.133). Short interest and short volume are non-trivial but manageable: days-to-cover as of the 07/15/2026 settlement is ~2.69, down from earlier higher levels, indicating available float to absorb directional moves but also the potential for rapid moves on catalyst-driven squeezes.
Valuation framing
At a market cap of ~$8.77B and a trailing P/E of ~9.24, XP trades at a discount both to many U.S. wealth managers and to what one would expect for a high-margin platform that reported record Q2 profit and expanded margins. The company’s P/B of 1.86x is reasonable for a financial services business with strong franchise economics and recurring fee potential.
This cheap multiple can be explained by concentrated country exposure (Brazil), legal overhang from mid-2025 investigations, and macro/rates sensitivity. If XP continues to grow assets (the 22% YoY figure is a useful guidepost) and executes on internationalization or tokenization partnerships, the market could re-rate the stock toward higher multiples. Conversely, further legal rulings or material outflows would justify the current discount.
Catalysts (what could drive the stock higher)
- Further quarterly reports showing sustained asset growth and margin expansion, which would validate the 2025 profit trends.
- Commercial adoption of its on-chain initiatives - partnership news (05/01/2026) around the Rayls public chain and early production usage would be a visible growth lever for fee income and cross-border payments.
- Resolution or de-escalation of legal investigations and short-seller allegations, which would remove a valuation overhang and could trigger multiple expansion.
- Improved macro environment in Brazil (lower inflation volatility / stabilizing rates) enabling investors to re-engage with domestic financial names.
Trade plan (actionable)
Entry: buy at $16.97 (market).
Stop loss: $15.00.
Target: $21.00.
Position horizon and rationale:
- Mid term (45 trading days) - This is our primary horizon. We expect one or two catalysts (quarterly data points, partnership updates or legal developments) to materialize within this window that could re-rate the stock to our $21 target. The trade is a swing that leans on both fundamentals (continued asset and earnings growth) and technicals (neutral-to-bullish indicators).
- Short term (10 trading days) - Expect volatility around news flow and macro moves. If the position quickly hits profit targets on a catalyst, scale out. If the stock moves down but holds the $15 stop, reassess on fresh data—avoid averaging into a materially broken market setup.
- Long term (180 trading days) - For investors who want longer exposure, the company’s mid-to-long-term optionality (international expansion, tokenization of assets, higher fee penetration) justifies holding through moderate volatility, but only after legal clarity and consistent earnings beats. If holding long-term, reassess when P/E moves above 12x without commensurate growth acceleration.
Trade sizing: keep the initial allocation modest (single-digit percent of risk capital) given the legal and macro overhangs. Use the $15 stop to define position size so that the downside per share is capped.
Risks and counterarguments
XP presents clear upside but also material risks. At least four specific risk vectors:
- Legal and reputational risk: multiple law firms' investigations and short-seller allegations surfaced in 04/2025 and 05/2025. Any adverse rulings or additional negative reports could compress multiples sharply and drive outflows.
- Macro and rates sensitivity: XP’s business depends on Brazilian client asset levels and market activity. Higher interest rates, elevated inflation or a sell-off in Brazilian assets could reduce fee volumes and AUM growth.
- Concentration and FX risk: the firm remains heavily Brazil-centric; currency depreciation or capital flight would hurt reported results in USD terms and investor sentiment.
- Execution risk on new initiatives: tokenization and cross-border projects carry execution and regulatory hurdles. Partnerships can take longer to monetize than anticipated, and early adoption may be slower.
Counterargument: one could argue XP’s cheap valuation already prices in legal uncertainty and Brazil exposure - but that assumes no new negative surprises. If investigations escalate or if client flows reverse materially, the stock could re-test FY lows near $14.80. That scenario justifies our tight stop and modest sizing. Also, the CEO has publicly signaled a challenging 2026 environment, so a conservative investor may prefer to wait for a clearer trend of quarterly beats before adding.
What would change my mind
I would downgrade the trade or reduce size if any of the following occur: (1) a material earnings miss accompanied by sizable net outflows, (2) a worsening legal ruling or credible evidence that undermines core client trust, (3) a macro shock that materially impairs Brazil asset markets and persists beyond a single quarter, or (4) persistent margin deterioration without signs of revenue diversification. Conversely, sustained double-digit asset growth and margin expansion accompanied by legal de-risking would prompt a stronger conviction and a higher price target.
Bottom line: XP is a tactical buy at $16.97 for a mid-term swing to $21 with a $15 stop. The company’s diversified distribution model, record profitability in recent quarters, and cheap P/E create an attractive asymmetric setup, provided investors respect the legal and macro risk vectors and size positions accordingly.
Key points
- XP trades at ~$8.77B market cap with a P/E of ~9.24 and P/B of ~1.86 - cheap for a profitable wealth platform.
- Record Q2 2025 net income (BRL 1.321B) and reported 22% YoY asset growth in 2025 show durable profitability and AUM expansion potential.
- On-chain and internationalization partnerships (e.g., Rayls, 05/01/2026) provide product and distribution optionality beyond Brazil.
- Primary risks are legal overhangs, Brazil macro sensitivity, and execution on new initiatives - use a hard stop at $15.
Trades to consider now
Buy at market $16.97. Target $21 in ~45 trading days; stop $15. If you prefer lower volatility, wait for an earnings beat or visible legal de-escalation and then buy on confirmation above $18.50 with the same $15 stop.
Note on recent news: XP was named as a partner in a May 01, 2026 announcement about the Rayls public chain, and the firm reported record Q2 profit in August 2025. Several law firms opened investigations in April-May 2025; these remain meaningful headline risk.